PKCι对维持KRAS突变结肠癌生存的作用及机制
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


PKCι maintains the survival of KRAS mutation colon cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 探讨PKCι在维持KRAS突变结肠癌生存中的作用及相关分子机制。方法 选取携KRAS突变的HCT116细胞和不携KRAS突变的RKO细胞为研究材料,两种细胞分别设置空白对照组(Control组)、ATM抑制组、shRNA-prkci组及shRNA-kras组。流式细胞术检测结肠癌细胞的凋亡及增殖情况。免疫印迹法(Western blot)和实时荧光定量PCR(qRT-PCR)检测KRAS、YAP1、PKCι的相对表达量。免疫荧光实验检测YAP1的表达。结果 在携KRAS突变的HCT116细胞中,PKCι的抑制伴随着细胞凋亡和生长抑制(均P<0.05);并且抑制PKCι可显著下调HCT116中YAP1的表达。而在不携带KRAS突变的RKO细胞中这种效应不明显。结论 PKCι通过调控YAP1维持KRAS突变结肠癌生存。PKCι与YAP1为潜在的结肠癌治疗靶标。

    Abstract:

    Objective To explore the effect of PKCι on maintaining the survival process of KRAS mutation colon cancer and its molecular mechanism.Methods HCT116 and RKO, colon cancer cells were selected and divided into blank control group, ATM group, shRNA-prkci group and shRNA-kras group. The apoptosis was determined by flow cytometry. Protein level and mRNA level were detected by western blot and qPCR. Cell location and relative expression of YAP1 were validated by immunofluorescence. Results In HCT116 cells carrying KRAS gene mutations, PKCι inhibition was accompanied by apoptosis and growth inhibition(P<0.05). Furthermore, inhibition of PKCι significantly down-regulated YAP1 expression in HCT116. This effect was not obvious in RKO cells without KAS mutation. Conclusion PKCι maintains the survival of KRAS mutant colon cancer by regulating the expression of YAP1.PKCι and YAP1 are potential targets for colon cancer with KRAS mutation.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-07-20
您是第位访问者
网站版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403 本网站支持 IPv6    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司